Board

Laxminarayan Bhat, Ph.D.

IMG_11032015_205815Laxminarayan Bhat is the Founder, President and Chief Executive Officer of Reviva Pharmaceuticals, Inc. Dr. Bhat founded Reviva in 2006 and since its inception, the company has advanced rapidly under his leadership, with a portfolio of propriety compounds at different stages in a pipeline encompassing chronic diseases in large therapeutic areas such as CNS, metabolic, cardiovascular and pain. Dr. Bhat has developed and implemented innovative financing and business models with strategies that have greatly accelerated the drug discovery and development process, resulting in significant savings of time and costs but without sacrificing quality.

Dr. Bhat has over 18 years’ experience in drug discovery and development and prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics and Higuchi Biosciences Center in the United States. Dr. Bhat has received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universität, Göttingen, Germany and the Université du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship, an internationally recognized award for young scientists to pursue advanced research in Germany. Dr. Bhat received his Ph.D. in synthetic organic chemistry from the Central University (NEHU), India and has authored over 15 research papers published in peer-reviewed scientific journals. Dr. Bhat is an inventor on more than 100 filed patents and over 35 granted patents.

Sarvajna Dwivedi, Ph.D.

IMG_11032015_205815Sarvajna is a pharmaceutical scientist with over 22 years of product development experience in large and small companies at various stages of development. Sarvajna co- founded Pearl in 2006 to develop inhaled medicines and their combinations for globally prevalent respiratory illnesses. Pearl raised $167.5M in venture capital, progressed three product candidates into Phase III clinical testing, and struck a $1.15b acquisition deal with AstraZeneca, all in about six years from its first funding in 2007. Pearl remains an independent group company with a much broader pipeline of products within AstraZeneca. Prior to his industrial career, Sarvajna conducted award-winning research in pharmaceutical sciences at the University of British Columbia in Canada, and was trained in pharmaceutics at Indian Institute of Technology, Banaras Hindu University. Sarvajna is a 2014 Ernst and Young Northern California Entrepreneur of the Year Finalist, a TiE Silicon Valley Charter Member, an advisor to emerging companies, and a mentor to entrepreneurs.

Peder K. Jensen, M.D.

IMG_11032015_205815Peder K Jensen has over 24 years of global drug development experience in both pharmaceutical and biotechnology companies and has been responsible for more than forty new drug approvals in the U.S., Europe and Japan during his career. He most recently served as Corporate Senior Vice President and General Manager, R&D for Japan and Asia/Pacific at Schering-Plough Corporation, and earlier he held a number of global senior R&D positions at Schering-Plough, including Senior Vice President of Clinical Research. Dr. Jensen previously held senior R&D positions at Chiron and Ciba-Geigy, and a number of academic posts. Dr Jensen is also a member of the Board of Acorda Therapeutics, BioCryst Pharmaceuticals and Five Prime Therapeutics. Dr. Jensen received his M.D. from the University of Copenhagen, where he also completed his post graduate medical training in neurology and internal medicine.

Purav Patel

Purav PatelPurav is the Founder and Managing Partner of Buena Vista Fund I, and also, a Serial Entrepreneur with 10+ years in active advisory, board, and fund-raising roles for 15+ privately held companies in various stages in healthcare and other fields. Purav served on the board of his portfolio companies, Healthify and Bindo. Purav has been with Reviva as an investor since 2009, and has a deep understanding of where the company has come from. Purav has worked directly with the Reviva management to secure funding over 4 investment rounds. Purav is highly analytical with a strong background in due diligence, financial analysis, and business operations. Purav graduated from the University of Texas with a Bachelors in Biology and Business.

TOP